— Decentralized Clinical Trials (DCT): Certification Program

Decentralized Clinical Trials (DCT): Certification Program

Build the operational, regulatory, and technology skills sponsors, CROs, biotechs, and health systems are hiring for to run decentralized and hybrid trials anywhere in the world — taught the way the industry actually delivers them.

Decentralized clinical trials (DCT) and hybrid trial designs have moved from pandemic-era workaround to industry standard. Sponsors, CROs, biotechs, regulators, and ministries of health are now embedding decentralized elements — eConsent, telehealth visits, direct-to-patient investigational product, wearables and sensors, ePRO/eClinRO, and home health visits — into trials across every therapeutic area and every region.
Empty space, drag to resize

Course Description

Decentralized clinical trials (DCT) and hybrid trial designs have moved from pandemic-era workaround to industry standard. Sponsors, CROs, biotechs, regulators, and ministries of health are now embedding decentralized elements — eConsent, telehealth visits, direct-to-patient investigational product, wearables and sensors, ePRO/eClinRO, and home health visits — into trials across every therapeutic area and every region. Qualified professionals who can plan, execute, and defend these trials remain in critically short supply.
This Professional Certification prepares clinical, regulatory, operations, and technology professionals to design, deliver, and inspection-defend hybrid and fully decentralized trials end-to-end. Across 17 modules — anchored to the 2024–2026 reference standards (FDA Final DCT Guidance Sept 2024, EMA Recommendation Paper, ICH E6(R3) Annex 2, Swissmedic+Swissethics DCT v3.2, NMPA Rare Disease DCT Technical Guiding Principles, Malaysia NCCR DCT Guidance) — you will work through the modern DCT playbook the industry is converging on: hybrid trial design, technology stack architecture, multi-regulator eConsent, remote monitoring and RBQM, telemedicine investigator workflows, direct-to-patient IP logistics, wearables and sensors, cross-border data governance, vendor selection, and inspection readiness.
The curriculum is taught with a genuinely global lens. Every operational module covers what FDA, EMA, MHRA, PMDA, NMPA, Swissmedic, Saudi FDA, UAE (DoH, DHA, MoHAP), Qatar MoPH, Singapore HSA, Malaysia NPRA, India CDSCO, AVAREF, SAHPRA, NAFDAC, EDA, and Kenya PPB expect — side by side, not as a footnote. You learn the hybrid trial the way regulators and sponsors actually negotiate it across jurisdictions.
Graduates leave with a CPD-accredited credential, a portfolio of worked artifacts (hybrid protocol synopsis, DCT operations plan, cross-border data governance plan, RBQM plan, and a mock inspection defense brief), and the vocabulary and judgment to lead DCT and hybrid trial work from day one — whether you are advancing inside your current organization or moving into your first DCT-focused role.

Designed and delivered by faculty with 27 years of clinical research leadership across North America, the GCC, Africa, and Asia-Pacific.

17 modules end-to-end DCT curriculum

A comprehensive journey through DCT fundamentals, 2026 regulations, ICH E6(R3), hybrid trials, digital technologies, data governance, compliance, and a practical capstone.

CPD-accredited credential

A portable professional certification recognized by sponsors, CROs, biotechs, and health systems across North America, EMEA, GCC, Africa, and Asia-Pacific.

Truly global, hybrid-first curriculum

Twenty-plus regulators across five regions covered side by side. Hybrid trial reality, not pure-DCT theory. Vendor-agnostic. Capstone includes a mock inspection defense — the only DCT certification on the market that does.

Aligned with 2025–2026 industry standards

Aligned with the latest global DCT guidance, including FDA, EMA, ICH E6(R3) Annex 2, Swissmedic, NMPA, and Malaysian NCCR frameworks.
Empty space, drag to resize

— Who this is for

Who this certification is for

The program is designed for clinical, regulatory, operations, and technology professionals moving into or expanding within decentralized and hybrid clinical trials. It is suited to:

  • CRAs, CRCs, and study managers transitioning from traditional site-based trials into decentralized and hybrid models.

  • Clinical operations leads, project managers, and study directors designing and delivering hybrid trials at sponsors and CROs.

  • Regulatory affairs professionals preparing DCT and hybrid trial submissions across FDA, EMA, MHRA, PMDA, NMPA, Swissmedic, GCC, India, and African regulators.
  • Data managers, biostatisticians, and informaticians building remote-data and hybrid trial pipelines.
  • Quality, GCP, and pharmacovigilance professionals expanding into remote monitoring, RBQM, and inspection readiness for distributed operations.
  • Pharmacists, physicians, and life-science graduates seeking globally portable careers in DCT and hybrid trial delivery.
  • Technology and vendor-side professionals working on eConsent, eCOA, telehealth, mobile health, DHT, and DCT platforms.
  • Public health, ministry of health, and health-system professionals applying DCT methodology to access, equity, and regional capacity-building.
  • Professionals building local DCT and hybrid trials capability and competing for regional and global roles.

— What’s included

Why Choose This Program

Career-ready outcomes

Graduates leave able to design a hybrid trial protocol, build a DCT operations plan, author a cross-border data governance plan, defend a study design to regulators, and respond to a mock inspection finding. The capstone portfolio is structured specifically to demonstrate hiring-relevant capability to sponsors, CROs, biotechs, and health systems.

Current industry methodology

The curriculum covers the methods regulators and sponsors expect in 2026 — hybrid design frameworks, decentralized element mapping, remote risk-based quality management, source-data verification in remote-source environments, fit-for-purpose digital health technologies under FDA DHT guidance, eConsent under FDA, EMA, ICH E6(R3) Annex 2, NMPA Rare Disease provisions, and inspection readiness for distributed operations. The program is updated continuously to reflect evolving industry and regulatory expectations.

Global curriculum with multi-regulator depth

Every operational module covers FDA, EMA, MHRA, PMDA, NMPA, Swissmedic, Saudi FDA, UAE (MoHAP, DoH Abu Dhabi, DHA Dubai), Qatar MoPH, Singapore HSA, Malaysia NPRA, India CDSCO, AVAREF, SAHPRA, NAFDAC, Egypt EDA, and Kenya PPB side by side. Plus an APAC sub-region matrix (MFDS Korea, BPOM Indonesia, Thailand FDA) and quick-reference for ANVISA, Health Canada, and TGA. Learners are positioned to compete for both regional and global DCT roles.

Designed for working professionals

Self-paced and fully online, with 12 months of platform access. No prior DCT experience is required. Learners complete the program with a CPD-accredited credential, a full portfolio of artifacts (hybrid protocol synopsis, DCT operations plan, cross-border data governance plan, RBQM plan, mock inspection defense brief), and a recorded capstone defense suitable to share with hiring managers and sponsors.

— A look inside the program

Become a Certified DCT Professional

Gain practical DCT skills with industry-focused training and certification.
Inside the RWE classroom
Live methodology walkthroughs

Course Curriculum

— Program outcomes

What you graduate with

The certification is designed to leave learners with a defensible body of work — not only a credential. Upon successful completion, graduates hold:

A complete hybrid trial protocol synopsis authored by the learner — with justified decentralized element mapping, defended in the capstone.
A DCT operations plan covering vendor selection, remote monitoring, DTP-IP logistics, eConsent, telemedicine investigators, and DHT integration.
A cross-border data governance plan satisfying GDPR, EHDS, UAE (Federal PDPL, DIFC, ADGM), Saudi PDPL, Qatar, India DPDP, POPIA, Nigeria NDPA, Kenya DPA, China PIPL, and US frameworks.
A risk-based quality management plan (KRIs, QTLs, monitoring strategy) for a hybrid trial.
A mock inspection defense brief — a written response to a simulated FDA 483 or EMA inspection finding on a distributed trial.

A CPD-accredited Professional Certification suitable for LinkedIn, CV, and sponsor or employer profiles.

Working fluency across the major DCT/hybrid frameworks and 20+ regulators in North America, EU, UK, Switzerland, GCC, Africa, India, Southeast Asia, and Asia-Pacific.

Twelve months of platform access for ongoing reference, refresh, and continuing professional development.

A professional positioning as a DCT and hybrid trials practitioner ready to lead distributed operations at sponsors, CROs, biotechs, or health systems.

Bundle offer